CBIO — Crescent Biopharma, Inc.
NASDAQ · Healthcare · Biotechnology
$18.66
+$0.73 (+4.10%)
Crescent Biopharma, Inc. (CBIO) is a biotechnology company listed on NASDAQ. It is led by Joshua T. Brumm, based in 300 Fifth Avenue, Waltham, MA, United States, 02451, with about 55 employees. Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
Net income was -$24.6M. CBIO currently screens at market cap $491.3M.
Use this CBIO page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CBIO quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CBIO SEC filings page. Lician reads the product cache first so this HTML stays unique to Crescent Biopharma, Inc. even when a live quote feed is slow.
About Crescent Biopharma, Inc.
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
CBIO Key Statistics
Market Cap
$491.31M
Volume
58,099
Previous Close
$16.97
Day Range
$17.02 – $17.65
P/B Ratio
2.78
EPS
-$0.59
Revenue
$0.00
Net Income
-$37.88M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
55
CBIO Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$37.88M | -$36.90M | -$46.69M | -$63.43M |
| EPS (Diluted) | -$0.59 | -$0.58 | -$0.89 | -$1.23 |
Total Assets
$11.09M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$10.72M
Operating Cash Flow
-$31.10M
Free Cash Flow
$0.00
Crescent Biopharma, Inc. Company Information
- CEO & Director
- Joshua T. Brumm
- Headquarters
- 300 Fifth Avenue, Waltham, MA, United States, 02451
- Website
- crescentbiopharma.com
- Phone
- 617 460 5595
- IPO / Founded
- 2014-01-10
- Sector
- Healthcare
- Industry
- Biotechnology